Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors

NCT ID NCT05512377

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if the drug could shrink tumors. However, the study was terminated early, so results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brigimadlin (BI 907828), an MDM2 inhibitor taken as a tablet
What this could lead to: If it works, this could provide a new treatment option for people with certain advanced cancers that have a specific genetic change (MDM2 amplification).
What could go wrong: This is an early-phase (Phase II) trial that was terminated, so results are limited. The drug may not shrink tumors or improve survival, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct adenocarcinoma biliary tract cancer Biliary Tract Neoplasms bladder transitional cell carcinoma lung adenocarcinoma lung neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BLADDER CANCER LUNG NEOPLASMS PANCREATIC NEOPLASMS SOLID TUMORS

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Austin Health

Heidelberg, Victoria, 3084, Australia
CTR Georges-François Leclerc

Dijon, 21079, France
China Medical University Hospital

Taichung, 404327, Taiwan
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Flinders Medical Centre

Bedford Park, South Australia, 5042, Australia
Fundación Jiménez Díaz

Madrid, 28040, Spain
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
ICON-South Brisbane-69267

South Brisbane, Queensland, 4101, Australia
Institut Gustave Roussy

Villejuif, 94805, France
Japanese Foundation for Cancer Research

Tokyo, Koto-ku, 135-8550, Japan
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Kanagawa Cancer Center

Kanagawa, Yokohama, 241-8515, Japan
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 80756, Taiwan
King Abdul Aziz Medical City

Riyadh, 11481, Saudi Arabia
Klinikum der Universität München AÖR

München, 81377, Germany
Krankenhaus Nordwest, Frankfurt

Frankfurt, 60488, Germany
LK Wiener Neustadt

Wiener Neustadt, 2700, Austria
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Medizinische Hochschule Hannover

Hanover, 30625, Germany
Memorial Sloan-Kettering Cancer Center

New York, New York, 10022, United States
National Cancer Center Hospital

Tokyo, Chuo-ku, 104-0045, Japan
National Cancer Center Hospital East

Chiba, Kashiwa, 277-8577, Japan
National Taiwan University Cancer Center

Taipei, 106, Taiwan
National University Hospital-Singapore-42005

Singapore, 119074, Singapore
Nebraska Cancer Specialists-Omaha-69066

Omaha, Nebraska, 68130, United States
Norton Cancer Institute, Downtown

Louisville, Kentucky, 40202, United States
Oncology Associates of Oregon, PC

Eugene, Oregon, 97401, United States
Ordensklinikum Linz GmbH - Barmherzige Schwestern

Linz, 4020, Austria
Oregon Health and Sciences University

Portland, Oregon, 97239, United States
Osaka International Cancer Institute

Osaka, Osaka, 541-8567, Japan
Perlmutter Cancer Center at NYU Langone Hospital - Long Island

Mineola, New York, 11501, United States
Prince of Wales Hospital-Randwick-66496

Randwick, New South Wales, 2031, Australia
Providence Medical Foundation-Santa Rosa -69764

Santa Rosa, California, 95403, United States
Rainbow Oncology

KwaZulu, 4126, South Africa
Rocky Mountain Cancer Centers-Lone Tree-69498

Lone Tree, Colorado, 80124, United States
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital

Seoul, 03722, South Korea
Songklanagarind Hospital

Hat Yai, 90110, Thailand
Southern Cancer Center

Mobile, Alabama, 36608, United States
Srinagarind Hospital

Muang, 40002, Thailand
Stanford Cancer Institute

Palo Alto, California, 94305, United States
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Tohoku University Hospital

Miyagi, Sendai, 980-8574, Japan
Universitair Ziekenhuis Antwerpen

Edegem, 2650, Belgium
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
University College Hospital

London, WC1E 6AG, United Kingdom
University Hospital Bern

Bern, 3010, Switzerland
University Hospital Geneva

Geneva, CH-1211, Switzerland
University of Arizona

Tucson, Arizona, 85719, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Southern California

Los Angeles, California, 90033-9173, United States
Universitätsklinikum Carl Gustav Carus Dresden

Dresden, 01307, Germany
Universitätsklinikum Ulm

Ulm, 89081, Germany
Yamaguchi University Hospital

Yamaguchi, Ube, 755-8505, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.